Literature DB >> 17960431

Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.

Luciano de Souza Viana1, José Carlos Serufo, Manoel Otávio da Costa Rocha, Renato Nogueira Costa, Roberto Carlos Duarte.   

Abstract

GOALS OF WORK: This is a prospective and observational study comparing the efficacy of risk-assessment models in patients with neutropenic fever in a reference treatment center. The meaning of the complex infection was evaluated.
MATERIALS AND METHODS: Patients were recruited throughout a 9-month period. Inclusion criteria were histologic diagnosis of malignancy, neutropenic febrile secondary to chemotherapy and/or radiotherapy (absolute neutrophil count of <500/microl and axillary temperature > or = 38 degrees C), and > or = 18 years of age. MAIN
RESULTS: Fifty-three febrile neutropenic patients were included. Twenty one of them were classified as low risk by the Multinational Association of Supportive Care in Cancer (MASCC) risk-index score. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of the MASCC risk-index scores were, respectively 87.9, 85.0, 90.6, 80.9, and 86.8%. None of the low-risk patients died, but four patients classified as low risk by the MASCC model developed serious medical complications during febrile neutropenic episodes. When we subtracted patients with complex infections from the group of patients with the MASCC risk-index score of > or = 21, we got 15 patients that were classified as low risk by a proposed adjustment by complex infection (PACI) model. None of them developed serious medical complications. The sensitivity, specificity, PPV, NPV, and the accuracy of this new model were, respectively, 100, 75.0, 86.8, 100, and 90.6%.
CONCLUSION: The MASCC risk-index score had high sensitivity and specificity to predict the absence of complications, but the PACI model was better than MASCC for predicting the absence of complications in this febrile neutropenic patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17960431     DOI: 10.1007/s00520-007-0347-3

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  15 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation.

Authors:  J A Talcott; R Finberg; R J Mayer; L Goldman
Journal:  Arch Intern Med       Date:  1988-12

Review 3.  New trends in patient management: risk-based therapy for febrile patients with neutropenia.

Authors:  K V Rolston
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

Review 4.  Infections in the neutropenic patient--new views of an old problem.

Authors:  G R Donowitz; D G Maki; C J Crnich; P G Pappas; K V Rolston
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2001

Review 5.  Risk assessment and treatment of low-risk patients with febrile neutropenia.

Authors:  Winfried V Kern
Journal:  Clin Infect Dis       Date:  2006-01-06       Impact factor: 9.079

6.  Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.

Authors:  Georgios Chamilos; Aristotle Bamias; Eleni Efstathiou; Pagona M Zorzou; Efstathios Kastritis; Evagelos Kostis; Christos Papadimitriou; Meletios A Dimopoulos
Journal:  Cancer       Date:  2005-06-15       Impact factor: 6.860

7.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

8.  Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials.

Authors:  L S Elting; E B Rubenstein; K V Rolston; G P Bodey
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

9.  Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.

Authors:  Almarie Uys; Bernardo L Rapoport; Ronald Anderson
Journal:  Support Care Cancer       Date:  2004-06-09       Impact factor: 3.603

10.  Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients.

Authors:  Carmen P Escalante; Mary Ann Weiser; Ellen Manzullo; Robert Benjamin; Edgardo Rivera; Tony Lam; Vi Ho; Rosalie Valdres; Eva Lu Lee; Noemi Badrina; Sally Fernandez; Yvette DeJesus; Kenneth Rolston
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

View more
  11 in total

1.  The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas.

Authors:  Xiao Jun Wang; Denise Yun Ting Goh; Sreemanee Raaj Dorajoo; Alexandre Chan
Journal:  Support Care Cancer       Date:  2017-04-11       Impact factor: 3.603

2.  A proposal for a simplified MASCC score.

Authors:  Jasmijn C A Wierema; Matthew Links
Journal:  Support Care Cancer       Date:  2012-12-18       Impact factor: 3.603

Review 3.  Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.

Authors:  Xiao Jun Wang; Alexandre Chan
Journal:  Curr Oncol Rep       Date:  2017-03       Impact factor: 5.075

4.  Validation of MASCC Score for Risk Stratification in Patients of Hematological Disorders with Febrile Neutropenia.

Authors:  M Taj; M Nadeem; S Maqsood; T Shah; T Farzana; T S Shamsi
Journal:  Indian J Hematol Blood Transfus       Date:  2016-10-01       Impact factor: 0.900

5.  Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network.

Authors:  Edwin Pun Hui; Linda K S Leung; Terence C W Poon; Frankie Mo; Vicky T C Chan; Ada T W Ma; Annette Poon; Eugenie K Hui; So-Shan Mak; Maria Lai; Kenny I K Lei; Brigette B Y Ma; Tony S K Mok; Winnie Yeo; Benny C Y Zee; Anthony T C Chan
Journal:  Support Care Cancer       Date:  2010-09-04       Impact factor: 3.603

Review 6.  Mitigating acute chemotherapy-associated adverse events in patients with cancer.

Authors:  Nicole M Kuderer; Aakash Desai; Maryam B Lustberg; Gary H Lyman
Journal:  Nat Rev Clin Oncol       Date:  2022-10-11       Impact factor: 65.011

7.  Febrile neutropenia studies in Brazil - treatment and cost management based on analyses of cases.

Authors:  Marcelo Bellesso
Journal:  Rev Bras Hematol Hemoter       Date:  2013

Review 8.  The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.

Authors:  Jean Klastersky; Marianne Paesmans
Journal:  Support Care Cancer       Date:  2013-02-27       Impact factor: 3.603

9.  Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis.

Authors:  Silvia Park; Cheol-In Kang; Doo Ryeon Chung; Kyong Ran Peck; Won Seog Kim; Seok Jin Kim
Journal:  Cancer Res Treat       Date:  2014-11-03       Impact factor: 4.679

10.  Frequency of bloodstream infection in febrile neutropenic patients, experience from a developing country.

Authors:  Basit Siddiqui; Rabeea Azmat; Shiyam Sunder Tikmani; Shumaila Rafi; Beenish Syed; Muhammad Tahir Khan; Hareem Rehman; Saleemullah Paracha
Journal:  Ann Med Surg (Lond)       Date:  2018-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.